References
- Hilgers JH. Pterygium: its incidence, heredity and etiology. Am J Ophthalmol. 1960 Oct;50:635–44. doi:https://doi.org/10.1016/0002-9394(60)90245-2.
- Bradley JC, Yang W, Bradley RH, Reid TW, Schwab IR. The science of pterygia. Br J Ophthalmol. 2010 Jul;94(7):815–20. doi:https://doi.org/10.1136/bjo.2008.151852.
- Chui J, Coroneo MT, Tat LT, Crouch R, Wakefield D, Di Girolamo N. Ophthalmic pterygium: a stem cell disorder with premalignant features. Am J Pathol. 2011 Feb;178(2):817–27. doi:https://doi.org/10.1016/j.ajpath.2010.10.037.
- Röck T, Bramkamp M, Bartz-Schmidt K-U, Röck D. A retrospective study to compare the recurrence rate after treatment of pterygium by conjunctival autograft, primary closure, and amniotic membrane transplantation. Med Sci Monit. 2019 Oct;25:7976–81. doi:https://doi.org/10.12659/MSM.915629.
- Kaufman SC, Jacobs DS, Lee WB, Deng SX, Rosenblatt MI, Shtein RM. Options and adjuvants in surgery for pterygium: a report by the American Academy of Ophthalmology. Ophthalmology. 2013 Jan;120(1):201–08. doi:https://doi.org/10.1016/j.ophtha.2012.06.066.
- Nuzzi R, Tridico F. How to minimize pterygium recurrence rates: clinical perspectives. Clin Ophthalmol. 2018;12:2347–62. doi:https://doi.org/10.2147/OPTH.S186543.
- Ang LP, Chua JL, Tan DT. Current concepts and techniques in pterygium treatment. Curr Opin Ophthalmol. 2007 Jul;18(4):308–13. doi:https://doi.org/10.1097/ICU.0b013e3281a7ecbb.
- Mearza AA, Aslanides IM, Ioannis M. Uses and complications of mitomycin C in ophthalmology. Expert Opin Drug Saf. 2007 Jan;6(1):27–32. doi:https://doi.org/10.1517/14740338.6.1.27.
- Jones RI, Rhee DJ, Douglas J. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006 Apr;17(2):163–67.
- Rønnov-Jessen L, Petersen OW. A function for filamentous alpha-smooth muscle actin: retardation of motility in fibroblasts. J Cell Biol. 1996 Jul;134(1):67–80. doi:https://doi.org/10.1083/jcb.134.1.67.
- Gabbiani G. The myofibroblast in wound healing and fibrocontractive diseases. J Pathol. 2003 Jul;200(4):500–03. doi:https://doi.org/10.1002/path.1427.
- Darby IA, Laverdet B, Bonté F, Desmoulière A. Fibroblasts and myofibroblasts in wound healing. Clin Cosmet Inv Derm. 2014;7:301–11.
- Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004 Mar;23(2):195–228.
- Kria L, Ohira A, Amemiya T. Immunohistochemical localization of basic fibroblast growth factor, platelet derived growth factor, transforming growth factor-beta and tumor necrosis factor-alpha in the pterygium. Acta Histochem. 1996 Apr;98(2):195–201. doi:https://doi.org/10.1016/S0065-1281(96)80038-9.
- Kria L, Ohira A, Amemiya T. Growth factors in cultured pterygium fibroblasts: immunohistochemical and ELISA analysis. Graefes Arch Clin Exp Ophthalmol. 1998 Aug;236(9):702–08. doi:https://doi.org/10.1007/s004170050144.
- Bourgier C, Haydont V, Milliat F, François A, Holler V, Lasser P, Bourhis J, Mathe D, Vozenin-Brotons MC. Inhibition of Rho kinase modulates radiation induced fibrogenic phenotype in intestinal smooth muscle cells through alteration of the cytoskeleton and connective tissue growth factor expression. Gut. 2005 Mar;54(3):336–43. doi:https://doi.org/10.1136/gut.2004.051169.
- Ji H, Tang H, Lin H, Mao J, Gao L, Liu J, Wu T. Rho/Rock cross-talks with transforming growth factor-β/Smad pathway participates in lung fibroblast-myofibroblast differentiation. Biomed Rep. 2014 Nov;2(6):787–92. doi:https://doi.org/10.3892/br.2014.323.
- Lee UE, Friedman SL. Mechanisms of hepatic fibrogenesis. Best Pract Res Clin Gastroenterol. 2011 Apr;25(2):195–206. doi:https://doi.org/10.1016/j.bpg.2011.02.005.
- Pan P, Shen M, Yu H, Li Y, Li D, Hou T. Advances in the development of Rho-associated protein kinase (ROCK) inhibitors. Drug Discov Today. 2013 Dec;18(23–24):1323–33. doi:https://doi.org/10.1016/j.drudis.2013.09.010.
- Feng Y, LoGrasso PV, Defert O, Li R. Rho Kinase (ROCK) inhibitors and their therapeutic potential. J Med Chem. 2016 Mar;59(6):2269–300. doi:https://doi.org/10.1021/acs.jmedchem.5b00683.
- Okumura N, Koizumi N, Ueno M, Sakamoto Y, Takahashi H, Hirata K, Torri R, Hamuro J, Kinoshita S. Enhancement of corneal endothelium wound healing by Rho-associated kinase (ROCK) inhibitor eye drops. Br J Ophthalmol. 2011 Jul;95(7):1006–09. doi:https://doi.org/10.1136/bjo.2010.194571.
- Sijnave D, Hollanders K, Van Bergen T, Van de Velde S, Vandewalle E, Moons L, Stalmans I. A RHO kinase inhibitor, AMA0526 improves corneal wound healing after alkali burn injury. Acta Ophthalmol. 2013 Aug;91(s252):1633. doi:https://doi.org/10.1111/j.1755-3768.2013.1633.x.
- Kita T, Hata Y, Arita R, Kawahara S, Miura M, Nakao S, Mochizuki Y, Enaida H, Goto Y, Shimokawa H, et al. Role of TGF-beta in proliferative vitreoretinal diseases and ROCK as a therapeutic target. Proc Natl Acad Sci. 2008 Nov 11;105(45):17504–09. doi:https://doi.org/10.1073/pnas.0804054105.
- Hollanders K, Van Bergen T, Kindt N, Castermans K, Leysen D, Vandewalle E, Moons L, Stalmans I. The effect of AMA0428, a novel and potent ROCK inhibitor, in a model of neovascular age-related macular degeneration. Invest Ophthalmol Vis Sci. 2015 Feb;56(2):1335–48. doi:https://doi.org/10.1167/iovs.14-15681.
- Honjo M, Tanihara H, Kameda T, Kawaji T, Yoshimura N, Araie M. Potential role of Rho-associated protein kinase inhibitor Y-27632 in glaucoma filtration surgery. Invest Ophthalmol Vis Sci. 2007 Dec;48(12):5549–57. doi:https://doi.org/10.1167/iovs.07-0878.
- Kaneko Y, Ohta M, Inoue T, Mizuno K, Isobe T, Tanabe S, Tanihara H. Effects of K-115 (Ripasudil), a novel ROCK inhibitor, on trabecular meshwork and Schlemm’s canal endothelial cells. Sci Rep. 2016 Jan 19;6:19640. doi:https://doi.org/10.1038/srep19640.
- Qin Z, Fu Q, Zhang L, Yin H, Jin X, Tang Q, Lyu D, Yao K. Proliferative effects of histamine on primary human pterygium fibroblasts. Mediat Inflamm. 2016;2016(11):9862496. doi:https://doi.org/10.1155/2016/9862496.
- Chen K, Lai K, Zhang X, Qin Z, Fu Q, Luo C, Jin X, Hu J, Liu S, Yao K. Bromfenac inhibits TGF-β1-induced fibrotic effects in human pterygium and conjunctival fibroblasts. Invest Ophthalmol Vis Sci. 2019 Mar;60(4):1156–64. doi:https://doi.org/10.1167/iovs.18-24743.
- Kim SW, Kim HI, Thapa B, Nuwromegbe S, Lee K. Critical role of mTORC2-Akt signaling in TGF-β1-induced myofibroblast differentiation of human pterygium fibroblasts. Invest Ophthalmol Vis Sci. 2019 Jan;60(1):82–92. doi:https://doi.org/10.1167/iovs.18-25376.
- Tian W, Fan Z, Li J, Hao C, Li M, Xu H, Wu X, Zhou B, Zhang L, Fang M, et al. Myocardin-related transcription factor A (MRTF-A) plays an essential role in hepatic stellate cell activation by epigenetically modulating TGF-β signaling. Int J Biochem Cell Biol. 2016 Feb;71:35–43. doi:https://doi.org/10.1016/j.biocel.2015.12.005.
- Xu H, Wu X, Qin H, Tian W, Chen J, Sun L, Fang M, Xu Y. Myocardin-related transcription factor A epigenetically regulates renal fibrosis in diabetic nephropathy. J Am Soc Nephrol. 2015 Jul;26(7):1648–60. doi:https://doi.org/10.1681/ASN.2014070678.
- Johnson LA, Rodansky ES, Haak AJ, Larsen SD, Neubig RR, Higgins PDR. Novel Rho/MRTF/SRF inhibitors block matrix-stiffness and TGF-β-induced fibrogenesis in human colonic myofibroblasts. Inflamm Bowel Dis. 2014 Jan;20(1):154–65. doi:https://doi.org/10.1097/01.MIB.0000437615.98881.31.
- Kim KW, Park SH, Kim JC. Fibroblast biology in pterygia. Exp Eye Res. 2016 Jan;142:32–39. doi:https://doi.org/10.1016/j.exer.2015.01.010.
- Branton MH, Kopp JB. TGF-β and fibrosis. Microbes Infect. 1999;1(15):1349–65. doi:https://doi.org/10.1016/S1286-4579(99)00250-6.
- Pohlers D, Brenmoehl J, Löffler I, Müller CK, Leipner C, Schultze-Mosgau S, Stallmach A, Kinne RW, Wolf G. TGF-beta and fibrosis in different organs - molecular pathway imprints. Biochim Biophys Acta. 2009 Aug;1792(8):746–56. doi:https://doi.org/10.1016/j.bbadis.2009.06.004.
- Chen YY, Tsai CF, Tsai MC, Chen WK, Hsu YW, Lu FJ. Anti-fibrotic effect of rosmarinic acid on inhibition of pterygium epithelial cells. Int J Ophthalmol. 2018 Feb;11(2):189–95.
- Meshkani SE, Kooshan N, Moghadam AB, Falanji F, Adli A, Arani FB, Baghbani-Arani F, Arian AG, Rad A. Signaling roadmap to epithelial–mesenchymal transition in pterygium, TWIST1 centralized. J Cell Physiol. 2019 Oct;234(10):18146–55. doi:https://doi.org/10.1002/jcp.28447.
- Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014 Feb;20(3):711–23. doi:https://doi.org/10.1158/1078-0432.CCR-13-1256.
- Muscella A, Vetrugno C, Cossa LG, Marsigliante S. TGF‐β1 activates RSC96 Schwann cells migration and invasion through MMP‐2 and MMP‐9 activities. J Neurochem. 2020 May;153(4):525–38. doi:https://doi.org/10.1111/jnc.14913.
- Feng QY, Hu ZX, Song XL, Pan HW. Aberrant expression of genes and proteins in pterygium and their implications in the pathogenesis. Int J Ophthalmol. 2017;10:973–81.
- Nuwormegbe SA, Sohn JH, Kim SW. A PPAR-gamma agonist rosiglitazone suppresses fibrotic response in human pterygium fibroblasts by modulating the p38 MAPK pathway. Invest Ophthalmol Vis Sci. 2017 Oct;58(12):5217–26. doi:https://doi.org/10.1167/iovs.17-22203.
- Loirand G. Rho kinases in health and disease: from basic science to translational research. Pharmacol Rev. 2015 Oct;67(4):1074–95. doi:https://doi.org/10.1124/pr.115.010595.
- Pattabiraman PP, Maddala R, Rao PV. Regulation of plasticity and fibrogenic activity of trabecular meshwork cells by Rho GTPase signaling. J Cell Physiol. 2014 Jul;229(7):927–42. doi:https://doi.org/10.1002/jcp.24524.
- Knipe RS, Tager AM, Liao JK. The Rho kinases: critical mediators of multiple profibrotic processes and rational targets for new therapies for pulmonary fibrosis. Pharmacol Rev. 2015 Jan;67(1):103–17. doi:https://doi.org/10.1124/pr.114.009381.
- Yamamoto M, Quantock AJ, Young RD, Okumura N, Ueno M, Sakamoto Y, Kinoshita S, Koizumi N. A selective inhibitor of the Rho kinase pathway, Y-27632, and its influence on wound healing in the corneal stroma. Mol Vis. 2012 Jun;18:1727–39.
- Zhang XH, Sun NX, Feng ZH, Wang C, Zhang Y, Wang JM. Interference of Y-27632 on the signal transduction of transforming growth factor beta type 1 in ocular Tenon capsule fibroblasts. Int J Ophthalmol. 2012;5:576–81.
- Korol A, Taiyab A, West-Mays JA. RhoA/ROCK signaling regulates TGFβ-induced epithelial-mesenchymal transition of lens epithelial cells through MRTF-A. Mol Med. 2016 Sep;22(1):713–23. doi:https://doi.org/10.2119/molmed.2016.00041.
- Small EM. The Actin-MRTF-SRF gene regulatory axis and myofibroblast differentiation. J Cardiovasc Trans Res. 2016 Jan;5(6):794–804. doi:https://doi.org/10.1007/s12265-012-9397-0.
- Olson EN, Nordheim A. Linking actin dynamics and gene transcription to drive cellular motile functions. Nat Rev Mol Cell Biol. 2010 May;11(5):353–65. doi:https://doi.org/10.1038/nrm2890.
- Miano JM, Long X, Fujiwara K. Serum response factor: master regulator of the actin cytoskeleton and contractile apparatus. Am J Physiol Cell Ph. 2007 Jan;292(1):C70–C81. doi:https://doi.org/10.1152/ajpcell.00386.2006.